Abstract
We estimate the U.S. temperature response curve for COVID-19 and show transmission is highly sensitive to temperature variation despite summer outbreaks widely assumed to show otherwise. By largely replacing the daily death counts states initially reported with counts based on death certificate date, we build a week-ahead statistical forecasting model that explains most of the daily variation (R2 = 0.97) and isolates COVID-19’s temperature response profile (p < 0.001). These counts normalized at 31°C (U.S. mid-summer average) scale up to nearly 160% at 5°C. Positive cases are more temperature sensitive, scaling up to almost 400% between 31°C and 5°C. Dynamic feedback amplifies these effects, suggesting that cooling temperatures are likely to the substantially increase COVID-19 transmission.
Article Summary Line COVID-19’s temperature response profile is reliably estimated using re-assembled state-reported data and suggests the onset of cold weather will amplify its spread.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Epidemiology study based on publicly available (non-individually identified) data.
Funding Statement
The authors declare no competing interests. The authors alone, and not their respective institutions, are responsible for the content of this paper. The contributions to this paper by S.L. Carson and T.K. Dye were done outside of their usual employment.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB approval required as only publicly available (non-individual identifiable) data (e.g., daily state-level COVID deaths) used.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data and code from the paper will be archived at github before publication.
